Andrea S.
- Country
- Italy
- Department
- SCDU Oncologia
Research Overview
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Ficlatuzumab and Cetuximab in Recurrent or Metastatic HPV-Negative Head and Neck Squamous Cell Carcinoma
- Evaluation of Pembrolizumab and Olaparib in Adult Patients with Recurrent/Metastatic, Platinum-Resistant Nasopharyngeal Carcinoma
- Evaluation of TransCon TLR7/8 Agonist and Pembrolizumab, Alone or Combined with TransCon IL-2 β/γ, in Stage III-IVA Resectable LA-HNSCC
Data & Insights
Has run more than one trial at 28 of 128 partner sites.
Specializations
Melanoma Research
This investigator specializes in advanced melanoma treatment, with particular focus on innovative immunotherapy approaches. Their research encompasses both resectable stage 3-4 melanoma and unresectable locally advanced or metastatic melanoma.
- Combination Immunotherapy Strategies
- Perioperative Therapy Approaches
- Novel Treatment Pathways
Their work explores new therapeutic combinations to enhance treatment outcomes in melanoma patients.
Head and Neck Cancer
The investigator conducts extensive research in head and neck squamous cell carcinoma (HNSCC), with specific attention to both locoregionally advanced and recurrent/metastatic disease.
- HPV-Negative HNSCC Treatment
- Immunotherapy Combinations
- Novel Therapeutic Approaches
Their research includes innovative treatment strategies for various stages of head and neck cancer.
Nasopharyngeal Cancer
The investigator focuses on developing treatments for recurrent/metastatic nasopharyngeal cancer, particularly in platinum-resistant cases. Their work explores combination therapy approaches.
- Targeted Therapy Combinations
- Treatment Resistance
- Novel Response Strategies
Research centers on improving outcomes for patients with advanced nasopharyngeal cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.